Dr. Vinay Prasad is back at the helm of the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research, returning less than two weeks after his political adversaries thought they had run him out of Washington—a victory that was short-lived.
“At the FDA’s request, Dr. Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research (CBER),” HHS spokesperson Andrew Nixon told The Hill in a statement. “Neither the White House nor HHS will allow the fake news media to distract from the critical work the FDA is carrying out under the Trump administration.”
Prasad, a hematologist-oncologist known for dismantling the shaky scientific premises that underpinned much of the COVID-19 response, took charge of the FDA’s biologics center in May. That center governs vaccines, gene therapies, and blood products — the very domains where the American people learned the hard way what happens when science is subordinated to politics.
The effort to oust him came to a head over Sarepta Therapeutics’ Elevidys, a gene therapy for Duchenne muscular dystrophy. On July 18, the FDA—under Prasad’s watch—told Sarepta to halt shipments after three deaths and mounting evidence that trial participants faced an unreasonable and significant risk of illness or injury. He also revoked the company’s prized platform technology designation. Sarepta initially refused. Four days later, the shipments stopped.
For some in the biotech world, that was the crime: an FDA regulator willing to say “no” to a powerful corporation. For activist Laura Loomer, it was political. She branded Prasad a “progressive leftist saboteur” and claimed his views were out of step with the administration’s mission. The pressure campaign intensified, amplified by a chorus of industry voices that preferred a regulator who would look the other way.
Prasad did not publicly comment on his resignation, but a spokesperson said he did “not want to be a distraction” to the FDA or the Trump administration.
Unofficially, the narrative was that the White House had pushed him out. But both FDA Commissioner Marty Makary and HHS Secretary Robert F. Kennedy Jr. went on record to say otherwise. Makary dismissed claims that Prasad had been fired as “simply untrue” and told reporters he was working to bring him back.
On August 9, the FDA confirmed Prasad’s reinstatement. The agency has not said whether he will also return as chief medical and scientific officer, a role he previously held in addition to directing the biologics center.
Wall Street, however, did not cheer. Biotech stocks fell sharply on news of his return, a signal that the industry expects him to enforce standards ignored under the Biden years. Sarepta slid more than 5 percent. Replimune, awaiting FDA decisions of its own, tumbled over 15 percent. In the investor world, a regulator with a spine is bad for business.
Prasad has already demonstrated what that spine looks like. Earlier this year, he and Makary authored a New England Journal of Medicine piece that rewrote the playbook for COVID-19 vaccines: limit boosters to those over 65 or at high risk, and require large-scale studies before expanding to younger populations. That is the kind of evidence-first policy shift that threatens the status quo of automatic, no-questions-asked approvals.
His return now poses a different question: Will he be given the latitude to keep doing it? Can he steer the agency through political and corporate crossfire without ceding ground to the forces that want the FDA to operate as a rubber stamp?
Prasad’s comeback is more than just a personnel decision. It is a signal that under the Trump administration, the FDA will not be handed over to corporate lobbyists or media narratives. Regulatory authority will be used to protect the public, not appease shareholders.
Those who tried to remove him underestimated two things: the resolve of this administration to defend its own, and Prasad’s unwillingness to surrender the field to those who would rather see safety sacrificed on the altar of speed and profit. The people who celebrated his resignation just watched him walk back in the door.
The coming months will show whether the agency—and its most controversial regulator—can hold the line. But for now, the message is unmistakable: the days of automatic approvals, political science, and corporate capture at the FDA are over.
